Developer docs
API playgroundTry for free, no card

Search company profiles

Embleema

Full company profile

uuid0000mt6

Namestring
Embleema
Legal namestring
Embleema Inc.
Websiteurl
embleema.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Embleema Inc. is a U.S.-based, privately held clinical data platform company founded in 2017 and headquartered in Metuchen, New Jersey (Delaware corporation). It builds the HIVE (High-Performance Integrated Virtual Environment) platform, a no-code, multimodal real-world data system designed for Phase IV and non-interventional research. The platform unifies electronic medical record data from 60,000+ care centers, 550+ wearables, genomic and biospecimen sources, and patient-reported outcomes into regulatory-grade datasets, with dynamic consent management, 21 CFR Part 11 audit trails, and CDISC-compliant outputs. Modular products include the core Embleema Platform, a Patient App, a Site Coordinator EDC, Dynamic Consent Management, Biospecimen Intelligence (built with Astoriom), the HIVE bioinformatics layer, and condition-specific communities such as the BET epilepsy registry co-developed with the Epilepsy Foundation.

The company serves three primary customer segments: pharmaceutical and biotech sponsors (e.g., Eisai, Galderma) seeking CRO-displacing RWE and registry infrastructure; academic research sites and investigators (Mayo Clinic, Johns Hopkins, NYU Langone) running multi-site registries; and patient advocacy organizations and patients (Lupus Research Alliance, Epilepsy Foundation, Epilepsy Study Consortium). Federal agencies (FDA, DoD, NIH) also use the platform for bioinformatics and regulatory analysis. Embleema operates a direct enterprise field-sales motion complemented by patient-community-led growth and event-driven demand generation (SCOPE, SCOPE Europe).

Embleema generates revenue primarily through a fixed-fee, multi-year subscription model for platform access, with module-based pricing and one-time study setup services. The model is positioned as 40% cheaper than traditional CRO approaches and targets cost overruns and long timelines in registry and real-world evidence programs. Pricing is not publicly disclosed. As of 2025, the company had raised approximately $3.7M in seed funding (Pharmagest, Techstars, 2019) with no subsequent priced round disclosed, employs 11-50 people, and reports penetration across 7 of the top 10 U.S. research institutions, with 100+ regulatory submissions supported at the FDA.

Short descriptiontext

Embleema builds the HIVE real-world data platform that unifies EHR, wearable, genomic, biospecimen, and patient-reported data into regulatory-grade datasets for Phase IV and non-interventional research, serving pharmaceutical sponsors, academic research sites, and patient advocacy organizations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical research platform, real-world evidence, patient registries, electronic data capture, clinical trial technology
Industry5 codes
PRIMARYHLACAOAA
Electronic Data Capture (EDC) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACAOAB
eCOA/ePRO/eDiary & Patient-Facing Data Collection
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACAAAJ
Clinical Forms, Templates & Digital Consent (eSignature)
Healthcare & Life Sciences/Digital Health & Health IT/Electronic Health Records (EHR/EMR) & Clinical Documentation
SECONDARYHLAGACAL
Site Data Management Support (EDC/Source/SDV Readiness)
SECONDARYHLAGAOAB
Data Management, Biostatistics & Statistical Programming FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
NAICS code4 codes
  • Software Publishers5132
  • Computer Systems Design and Related Services54151
  • Custom Computer Programming Services541511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Services-Prepackaged Software7372
  • Services-Computer Programming, Data Processing, Etc.7370
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Research Technology / Real-World Evidence Platform
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Platform Subscription / Fixed-Fee
TypeSubscription Recurring
Description

Fixed-fee pricing model for platform access and study setup. Sponsors pay for modules they use with predictable budgets from day one. Model positions as lower cost alternative to traditional CRO technology stacks while providing access to full team and platform capabilities.

embleema.com
2Study Setup and Configuration Services
TypeProfessional Services
Description

Team sets up each study using flexible no-code platform. One-time setup fees integrated into fixed-fee structure with no hidden costs or upsells.

embleema.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Fixed-fee platform access with module-based pricing
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Fixed-fee model where sponsors only pay for modules they use. Transparent, predictable pricing avoids upsells and unused features common with traditional CRO stacks.

embleema.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Embleema sells a unified, no-code multimodal real-world data platform for Phase IV and non-interventional research that captures and integrates EHR, genomic, clinical, biospecimen, wearable, and patient-reported data into regulatory-grade datasets. The platform bundles a Site Coordinator EDC, a Patient App, the HIVE bioinformatics engine, Dynamic Consent Management, and condition-specific patient community modules (e.g., BET for epilepsy) and is licensed primarily to pharmaceutical sponsors, biotech firms, and academic research centers on a fixed-fee subscription with setup services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 40% lower cost than traditional Phase IV/non-interventional research approaches
+7 more records
Product overview1 text field

Embleema is a unified, multimodal real-world data platform designed for Phase IV and non-interventional research. The core Embleema Platform combines patient and site applications with genomic, clinical, and patient-reported data to deliver multimodal datasets in weeks at 40% lower cost. The architecture includes: the core Platform (configurable no-code EDC with EHR integration from 60,000+ care centers), Patient App (for symptom tracking and data sharing), Site Coordinator Platform (EDC with EMR pre-fills and quality controls), Dynamic Consent Management (standalone consent governance layer), Biospecimen Intelligence (specimen-consent-data unification), the HIVE bioinformatics platform (regulatory analytics), and the BET epilepsy registry app. Additional modules include the Patient Community Network for recruitment and the Integrated Specimen Management Suite (powered by Embleema and Astoriom).

Product and service5 records
1Embleema Platform (Core Multimodal Real-World Data Platform)
CategoryClinical research / real-world evidence platform
Description

Unified, no-code multimodal real-world data platform for Phase IV and non-interventional research that captures and integrates EHR, genomic, clinical, biospecimen, wearable, and patient-reported data into regulatory-grade datasets; sold to pharmaceutical sponsors, biotech firms, and academic research centers on a fixed-fee subscription with study-setup services.

2Patient App
CategoryPatient-facing clinical research application
Description

Mobile-first patient application enabling symptom tracking, seizure logging, medication monitoring, wearable data sync, and EHR connection; returns data to patients and delivers personalized services to enhance engagement and adherence for use by patients participating in sponsor-led studies.

3Site Coordinator Platform (EDC)
CategoryElectronic Data Capture (EDC) / site tooling
Description

Advanced Electronic Data Capture (EDC) system for research sites with EMR integration, drag-and-drop PDF-to-eCRF conversion, real-time edit checks, and customizable workflows; includes role-based task lists, pre-filled data fields, and integrated quality control tools for academic medical centers and investigator sites.

4HIVE Platform (High-Performance Integrated Virtual Environment)
CategoryBioinformatics / regulatory analytics platform
Description

Bioinformatics and regulatory analytics platform that transforms raw data from connected devices, trackers, and medical records into regulatory-grade evidence; ensures data provenance and regulatory compliance for clinical research, regulatory submissions, and use by agencies such as the FDA and DoD.

5BET (Battling Epilepsy Together) Platform
CategoryDisease-specific patient registry platform
Description

Patient-first epilepsy registry and self-management app co-developed with the Epilepsy Foundation and Dr. Jacqueline French; enables seizure logging, EMR integration, medication tracking, and clinical trial recruitment with multilingual, mobile-first design for epilepsy patients and research sponsors.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-26
Description

Strategic partnership to provide end-to-end biospecimen management solution. Embleema provides consent management and clinical data platform while Astoriom delivers sample storage and biorepository services. Joint solution addresses biosample reuse challenges with integrated consent tracking and sample lifecycle governance.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-12-07
Description

Partnership to deploy next-generation clinical research solutions for life sciences. CALYM is a nonprofit research consortium focused on lymphoma research. Collaboration enables better data management and patient engagement for lymphoma clinical studies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-developed the Battling Epilepsy Together (BET) platform - a patient-first epilepsy registry serving as both a self-management app and research engine. Partnership enables patient recruitment and engagement for epilepsy research initiatives.

4Dr. Jacqueline French / Epilepsy Study Consortium
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-development of BET platform with Dr. Jacqueline French, Neurology Professor and Epilepsy Study Consortium President. Dr. French provides clinical expertise and leads the Human Epilepsy Project using the platform.

embleema.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Platform originally developed in collaboration with FDA. Currently used by FDA for bioinformatics analysis of cell and gene therapies regulatory approvals. Powers mission-critical research for FDA, DoD, and NIH.

6DoD (Department of Defense)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Embleema platform used by DoD for analyzing complex genomic data. Supports mission-critical research initiatives for defense health programs.

embleema.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Platform trusted by NIH for research initiatives. Part of federal health research ecosystem using Embleema for regulatory-grade data management.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Veeva Vault Clinical and CDB platforms provide EDC, CTMS, and eTMF for life sciences. Competes with Embleema in the unified clinical data platform category, particularly with larger enterprise sponsors that prefer Veeva's broader application suite.

TypeDirect peer
Description

Real-world evidence network and federated query platform used by pharma sponsors and academic medical centers. Comparable to Embleema in connecting EHR data for observational research and clinical trial feasibility, with a strong footprint in academic medical centers.

TypeBroad incumbent
Description

Largest CRO and clinical data analytics incumbent — and notably the former employer of Embleema's CEO. Competes with Embleema across RWE, EDC, and clinical operations services; IQVIA's E360 platform and Orchestrated Customer Engagement overlap directly with Embleema's value proposition.

TypeEmerging player
Description

Cloud-based EDC platform focused on decentralized and hybrid clinical trials. Comparable to Embleema on eCRF build speed, integrations, and direct-to-site usability, though with less multimodal/wearables and consent depth.

TypeDirect peer
Description

Industry-leading EDC and clinical trial technology platform used by the majority of large pharma sponsors. Directly comparable to Embleema on EDC, eCOA/ePRO, and clinical data management, but at vastly greater scale and with broader protocol coverage.

TypeDirect peer
Description

Specializes in eCOA, ePRO, and patient-centric clinical outcome assessments — directly overlapping with Embleema's Patient App and ePRO capture capabilities. A meaningful peer for sponsors evaluating patient-reported data capture quality and engagement.

TypeEmerging player
Description

AI-driven multimodal clinical and omics data platform for pharma research. Comparable to Embleema on multimodal data integration and AI-powered evidence generation, though Owkin focuses more on AI/ML model development than EDC and registries.

TypeEmerging player
Description

Health data connectivity and tokenization layer that links disparate patient datasets for research. Comparable to Embleema in the RWE data-unification layer, though more horizontal and infrastructure-oriented than Embleema's full-stack EDC + registry platform.

TypeDirect peer
Description

Generates clinical evidence via eCOA, medical imaging, cardiac safety, and wearables integrations. Comparable to Embleema on wearable data capture and multimodal evidence generation, with stronger scale in cardiac and imaging endpoints.

TypeDirect peer
Description

Oracle's unified clinical trial platform (acquired from Phase Forward and goBalto) competes head-on with Embleema in EDC, RTSM, and clinical data management for pharma and CROs, with deep integration into Oracle's broader health and analytics stack.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Embleema

Clinical Research Technology / Real-World Evidence Platformembleema.com

Embleema builds the HIVE real-world data platform that unifies EHR, wearable, genomic, biospecimen, and patient-reported data into regulatory-grade datasets for Phase IV and non-interventional research, serving pharmaceutical sponsors, academic research sites, and patient advocacy organizations.

What Embleema does

Embleema Inc. is a U.S.-based, privately held clinical data platform company founded in 2017 and headquartered in Metuchen, New Jersey (Delaware corporation). It builds the HIVE (High-Performance Integrated Virtual Environment) platform, a no-code, multimodal real-world data system designed for Phase IV and non-interventional research. The platform unifies electronic medical record data from 60,000+ care centers, 550+ wearables, genomic and biospecimen sources, and patient-reported outcomes into regulatory-grade datasets, with dynamic consent management, 21 CFR Part 11 audit trails, and CDISC-compliant outputs. Modular products include the core Embleema Platform, a Patient App, a Site Coordinator EDC, Dynamic Consent Management, Biospecimen Intelligence (built with Astoriom), the HIVE bioinformatics layer, and condition-specific communities such as the BET epilepsy registry co-developed with the Epilepsy Foundation.

The company serves three primary customer segments: pharmaceutical and biotech sponsors (e.g., Eisai, Galderma) seeking CRO-displacing RWE and registry infrastructure; academic research sites and investigators (Mayo Clinic, Johns Hopkins, NYU Langone) running multi-site registries; and patient advocacy organizations and patients (Lupus Research Alliance, Epilepsy Foundation, Epilepsy Study Consortium). Federal agencies (FDA, DoD, NIH) also use the platform for bioinformatics and regulatory analysis. Embleema operates a direct enterprise field-sales motion complemented by patient-community-led growth and event-driven demand generation (SCOPE, SCOPE Europe).

Embleema generates revenue primarily through a fixed-fee, multi-year subscription model for platform access, with module-based pricing and one-time study setup services. The model is positioned as 40% cheaper than traditional CRO approaches and targets cost overruns and long timelines in registry and real-world evidence programs. Pricing is not publicly disclosed. As of 2025, the company had raised approximately $3.7M in seed funding (Pharmagest, Techstars, 2019) with no subsequent priced round disclosed, employs 11-50 people, and reports penetration across 7 of the top 10 U.S. research institutions, with 100+ regulatory submissions supported at the FDA.

Embleema firmographics

Firmographics
Name
Embleema
Legal name
Embleema Inc.
Website
https://embleema.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Embleema builds the HIVE real-world data platform that unifies EHR, wearable, genomic, biospecimen, and patient-reported data into regulatory-grade datasets for Phase IV and non-interventional research, serving pharmaceutical sponsors, academic research sites, and patient advocacy organizations.
Ownership category
akta.pro rank

Embleema industry classification

Industry
Product category
Clinical Research Technology / Real-World Evidence Platform
NAICS
Software Publishers (5132), Computer Systems Design and Related Services (54151), Custom Computer Programming Services (541511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Prepackaged Software (7372), Services-Computer Programming, Data Processing, Etc. (7370), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLACAOAA
Electronic Data Capture (EDC) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACAOAB
eCOA/ePRO/eDiary & Patient-Facing Data Collection
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACAAAJ
Clinical Forms, Templates & Digital Consent (eSignature)
Healthcare & Life Sciences/Digital Health & Health IT/Electronic Health Records (EHR/EMR) & Clinical Documentation
SECONDARYHLAGACAL
Site Data Management Support (EDC/Source/SDV Readiness)
SECONDARYHLAGAOAB
Data Management, Biostatistics & Statistical Programming FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)

Keywords

  • Clinical research platform
  • Real-world evidence
  • Patient registries
  • Electronic data capture
  • Clinical trial technology

Where Embleema is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Embleema business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Platform Subscription / Fixed-Fee: Fixed-fee pricing model for platform access and study setup. Sponsors pay for modules they use with predictable budgets from day one. Model positions as lower cost alternative to traditional CRO technology stacks while providing access to full team and platform capabilities.
  2. Study Setup and Configuration Services: Team sets up each study using flexible no-code platform. One-time setup fees integrated into fixed-fee structure with no hidden costs or upsells.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractFixed-fee platform access with module-based pricing

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Embleema product offering

Product offering

Core offering

Embleema sells a unified, no-code multimodal real-world data platform for Phase IV and non-interventional research that captures and integrates EHR, genomic, clinical, biospecimen, wearable, and patient-reported data into regulatory-grade datasets. The platform bundles a Site Coordinator EDC, a Patient App, the HIVE bioinformatics engine, Dynamic Consent Management, and condition-specific patient community modules (e.g., BET for epilepsy) and is licensed primarily to pharmaceutical sponsors, biotech firms, and academic research centers on a fixed-fee subscription with setup services.

Product overview

Embleema is a unified, multimodal real-world data platform designed for Phase IV and non-interventional research. The core Embleema Platform combines patient and site applications with genomic, clinical, and patient-reported data to deliver multimodal datasets in weeks at 40% lower cost. The architecture includes: the core Platform (configurable no-code EDC with EHR integration from 60,000+ care centers), Patient App (for symptom tracking and data sharing), Site Coordinator Platform (EDC with EMR pre-fills and quality controls), Dynamic Consent Management (standalone consent governance layer), Biospecimen Intelligence (specimen-consent-data unification), the HIVE bioinformatics platform (regulatory analytics), and the BET epilepsy registry app. Additional modules include the Patient Community Network for recruitment and the Integrated Specimen Management Suite (powered by Embleema and Astoriom).

Differentiator

Problem solved

Functional benefit

Products and services

  • Embleema Platform (Core Multimodal Real-World Data Platform) Unified, no-code multimodal real-world data platform for Phase IV and non-interventional research that captures and integrates EHR, genomic, clinical, biospecimen, wearable, and patient-reported data into regulatory-grade datasets; sold to pharmaceutical sponsors, biotech firms, and academic research centers on a fixed-fee subscription with study-setup services.
  • Patient App Mobile-first patient application enabling symptom tracking, seizure logging, medication monitoring, wearable data sync, and EHR connection; returns data to patients and delivers personalized services to enhance engagement and adherence for use by patients participating in sponsor-led studies.
  • Site Coordinator Platform (EDC) Advanced Electronic Data Capture (EDC) system for research sites with EMR integration, drag-and-drop PDF-to-eCRF conversion, real-time edit checks, and customizable workflows; includes role-based task lists, pre-filled data fields, and integrated quality control tools for academic medical centers and investigator sites.
  • HIVE Platform (High-Performance Integrated Virtual Environment) Bioinformatics and regulatory analytics platform that transforms raw data from connected devices, trackers, and medical records into regulatory-grade evidence; ensures data provenance and regulatory compliance for clinical research, regulatory submissions, and use by agencies such as the FDA and DoD.
  • BET (Battling Epilepsy Together) Platform Patient-first epilepsy registry and self-management app co-developed with the Epilepsy Foundation and Dr. Jacqueline French; enables seizure logging, EMR integration, medication tracking, and clinical trial recruitment with multilingual, mobile-first design for epilepsy patients and research sponsors.

Quantifiable outcome

  • 40% lower cost than traditional Phase IV/non-interventional research approaches
  • +7 more outcomes

Companies that use Embleema

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Embleema technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability5 records

Feature5 records

Embleema partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and major.

  • AstoriomcoreStrategic or Co-development Partner · 26 November 2025Strategic partnership to provide end-to-end biospecimen management solution. Embleema provides consent management and clinical data platform while Astoriom delivers sample storage and biorepository services. Joint solution addresses biosample reuse challenges with integrated consent tracking and sample lifecycle governance.
  • CALYMmajorStrategic or Co-development Partner · 7 December 2022Partnership to deploy next-generation clinical research solutions for life sciences. CALYM is a nonprofit research consortium focused on lymphoma research. Collaboration enables better data management and patient engagement for lymphoma clinical studies.
  • Epilepsy FoundationcoreStrategic or Co-development PartnerCo-developed the Battling Epilepsy Together (BET) platform - a patient-first epilepsy registry serving as both a self-management app and research engine. Partnership enables patient recruitment and engagement for epilepsy research initiatives.
  • Dr. Jacqueline French / Epilepsy Study ConsortiumcoreStrategic or Co-development PartnerCo-development of BET platform with Dr. Jacqueline French, Neurology Professor and Epilepsy Study Consortium President. Dr. French provides clinical expertise and leads the Human Epilepsy Project using the platform.
  • FDA (U.S. Food and Drug Administration)coreStrategic or Co-development PartnerPlatform originally developed in collaboration with FDA. Currently used by FDA for bioinformatics analysis of cell and gene therapies regulatory approvals. Powers mission-critical research for FDA, DoD, and NIH.
  • DoD (Department of Defense)coreStrategic or Co-development PartnerEmbleema platform used by DoD for analyzing complex genomic data. Supports mission-critical research initiatives for defense health programs.
  • NIH (National Institutes of Health)coreStrategic or Co-development PartnerPlatform trusted by NIH for research initiatives. Part of federal health research ecosystem using Embleema for regulatory-grade data management.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Embleema competitors and assessment

Company assessment

Direct peers

  • Veeva Systems: Veeva Vault Clinical and CDB platforms provide EDC, CTMS, and eTMF for life sciences. Competes with Embleema in the unified clinical data platform category, particularly with larger enterprise sponsors that prefer Veeva's broader application suite.
  • TriNetX: Real-world evidence network and federated query platform used by pharma sponsors and academic medical centers. Comparable to Embleema in connecting EHR data for observational research and clinical trial feasibility, with a strong footprint in academic medical centers.
  • Medidata (Dassault Systèmes): Industry-leading EDC and clinical trial technology platform used by the majority of large pharma sponsors. Directly comparable to Embleema on EDC, eCOA/ePRO, and clinical data management, but at vastly greater scale and with broader protocol coverage.
  • Signant Health: Specializes in eCOA, ePRO, and patient-centric clinical outcome assessments — directly overlapping with Embleema's Patient App and ePRO capture capabilities. A meaningful peer for sponsors evaluating patient-reported data capture quality and engagement.
  • Clario: Generates clinical evidence via eCOA, medical imaging, cardiac safety, and wearables integrations. Comparable to Embleema on wearable data capture and multimodal evidence generation, with stronger scale in cardiac and imaging endpoints.
  • Oracle Clinical One: Oracle's unified clinical trial platform (acquired from Phase Forward and goBalto) competes head-on with Embleema in EDC, RTSM, and clinical data management for pharma and CROs, with deep integration into Oracle's broader health and analytics stack.

Broad incumbents

  • IQVIA: Largest CRO and clinical data analytics incumbent — and notably the former employer of Embleema's CEO. Competes with Embleema across RWE, EDC, and clinical operations services; IQVIA's E360 platform and Orchestrated Customer Engagement overlap directly with Embleema's value proposition.

Emerging players

  • Castor: Cloud-based EDC platform focused on decentralized and hybrid clinical trials. Comparable to Embleema on eCRF build speed, integrations, and direct-to-site usability, though with less multimodal/wearables and consent depth.
  • Owkin: AI-driven multimodal clinical and omics data platform for pharma research. Comparable to Embleema on multimodal data integration and AI-powered evidence generation, though Owkin focuses more on AI/ML model development than EDC and registries.
  • Datavant: Health data connectivity and tokenization layer that links disparate patient datasets for research. Comparable to Embleema in the RWE data-unification layer, though more horizontal and infrastructure-oriented than Embleema's full-stack EDC + registry platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Embleema social profiles

Digital presence

Embleema compliance and trust

Trust signal

Compliance7 records

Embleema financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Embleema leadership team

Management profile

Number of profiles

Profiles10 records

Embleema funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Embleema M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Embleema

What does Embleema do?

Embleema sells a unified, no-code multimodal real-world data platform for Phase IV and non-interventional research that captures and integrates EHR, genomic, clinical, biospecimen, wearable, and patient-reported data into regulatory-grade datasets. The platform bundles a Site Coordinator EDC, a Patient App, the HIVE bioinformatics engine, Dynamic Consent Management, and condition-specific patient community modules (e.g., BET for epilepsy) and is licensed primarily to pharmaceutical sponsors, biotech firms, and academic research centers on a fixed-fee subscription with setup services.

Is Embleema a public or private company?

Embleema is a private company. It is classified as venture growth investor backed and is currently operating.

When was Embleema founded?

Embleema was founded in 2017. It employs 11 to 50 people.

Where is Embleema based?

Embleema is headquartered in New York, United States, in the North America region.

How does Embleema make money?

Two revenue lines are on record. Platform Subscription / Fixed-Fee is the primary driver. The others are study Setup and Configuration Services.

Who are Embleema's main competitors?

Direct peers on record are Veeva Systems, TriNetX, Medidata (Dassault Systèmes), Signant Health, Clario and Oracle Clinical One. IQVIA is listed as a broad incumbent. Emerging players are Castor, Owkin and Datavant.

Does Embleema have an API?

No public API is recorded for Embleema.

What industry is Embleema in?

Embleema's product category is Clinical Research Technology / Real-World Evidence Platform. Its primary akta.pro industry code is HLACAOAA, Electronic Data Capture (EDC) Platforms, with a secondary code of HLACAOAB, eCOA/ePRO/eDiary & Patient-Facing Data Collection. Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyWhy decentralized longevity trials live or die by data architectureDecentralized longevity trials require secure data architecture and regulatory compliance to enable cross-border data exchange. Case studies from Trials@Home, HCLTech, DataMotion, and Embleema illustrate integration challenges and retention rates. Early planning for data governance can support international expansion and biomarker endpoint evaluation.openPR.comBlockchain Technology in Healthcare Market 2025: Growth, Applications, Innovations and Business Outlook by 2032 | ConsenSys, Embleema, Equideum Health, IBM LifescienceThe blockchain technology in healthcare market is estimated at USD 194.5 million in 2025, projected to reach USD 796.0 million by 2032, a CAGR of 22.3%. The report from CoherentMI covers key players, applications, and growth drivers.openPR.comFuture-Proofing Growth Blockchain Technology in Healthcare Market, Size, Analytical Overview, Growth Factors, Demand and Trends Forecast to 2032 : ConsenSys, Embleema, Equideum Health, IBM LifescienceCoherentMI's market research report forecasts the blockchain technology in healthcare market to grow from USD 159 million in 2024 to USD 641 million by 2031, a CAGR of 22.1%. The study also profiles key players including ConsenSys, Embleema, Equideum Health, and IBM Lifescience, and segments the market by application and blockchain type.GlobeNewswireGlobal Blockchain Technology in Healthcare Market Report 2022 to 2028: Featuring IBM, Oracle, Hashed Health and Embleema Among OthersThe global blockchain technology in healthcare market is projected to reach $5.3 billion by 2028, growing at a 39.9% CAGR. The report highlights blockchain's role in combating pharmaceutical counterfeiting and improving data security, with key players including IBM, Oracle, Hashed Health, and Embleema.Business Wire BlogCALYM and Embleema Announce Partnership to Deploy Next-Generation Clinical Research Solutions for Life SciencesCALYM Carnot Institute and Embleema announced a strategic partnership to develop next-generation clinical research solutions for lymphoma. The collaboration aims to improve patient recruitment, consent management, and regulatory-grade evidence generation. Embleema's HIVE platform is used by the FDA for genomic data evaluation.U.S. Food and Drug AdministrationExpanding next-generation sequencing tools to support pandemic preparedness and responseEmbleema and George Washington University are conducting bioinformatic research to expand the FDA-ARGOS microbial sequence database under a contract funded by the FDA. The project, valued at $3.47 million in its 2022 option award, aims to develop quality control tools and mining capabilities to incorporate high-quality sequences from public databases. This initiative seeks to enhance the utility of FDA-ARGOS for medical countermeasure development and pandemic preparedness.Business Wire BlogAlira Health and Embleema Announce Partnership to Deploy Next-Generation Real-World Data Solutions for Life SciencesAlira Health and Embleema announced a strategic partnership to develop next-generation real-world data solutions for healthcare and life sciences. The collaboration aims to improve patient outcomes through regulatory-grade evidence and seamless data exchange. Embleema's HIVE platform, used by the FDA, will be integrated into the partnership.GlobeNewswirePHARMAGEST INTERACTIVE : 2018 revenuePharmagest Group reported 2018 revenue of €148.48 million, up 14.51% year-on-year, with pro forma growth of 8.3%. All divisions achieved gains, and the outlook for 2019 is positive, driven by strategic partnerships and the acquisition of an equity stake in Embleema.Business Wire BlogEmbleema Closes $3.7M Series A Funding Round and Joins Techstars Alchemist Blockchain Accelerator ProgramEmbleema closed a $3.7M Series A funding round led by Pharmagest and Techstars. The funds will accelerate blockchain-based health applications and commercial deployment. The company will join the Techstars Alchemist Blockchain accelerator to access mentors and investment.VC News DailyEmbleema Closes $3.7M Series A FundingEmbleema, a blockchain healthcare company, closed a $3.7 million Series A funding round led by Pharmagest, a European pharmacy software group, and Techstars. The company plans to use the funds to accelerate development of blockchain-based applications for patients and pharmacies, and to support commercial deployment of its PatientTruth platform launched in the US in July 2018. Embleema has also joined the 3-month Alchemist Blockchain Techstars Accelerator program to access mentorship and accelerate development of a decentralized marketplace for sharing Real World Evidence and Clinical Data.